Edwards D, Jones P, Haramis H, et al. 99mTc-NC100692——a tracer for imaging vitronectin receptors associated with angiogenesis: a preclinical investigation[J]. Nucl Med Biol, 2008,35(3): 365-375.
[8]
Roed L, Oulie I, McParland BJ, et al. Human urinary excretion of NC100692, a RGDpeptide for imaging angiogenesis[J]. Eur J Pharm Sci, 2009, 37(3-4): 79-83.
[9]
Raguse JD, Gath HJ, Bier J, et al. Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour[J]. Oral Oncol, 2004, 40(2): 228-230.
[10]
Ruoslahti E, Pierschbacher MD. Arg-Gly-Asp: a versatile cell recognition signal[J]. Cell, 1986, 44(4): 517-518.
[11]
Wester HJ, Schottelius M, Scheidhauer K, et al. Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydration on the pharmacokinetics[J]. Eur J Nucl Med Mol Imaging, 2002, 29(1): 28-38.
[12]
Chen X, Tohme M, Park R, et al. MicroPET imaging of alphavbeta3integrin expression with 18F-labeled dimeric RGD peptide[J]. Mol Imaging, 2004, 3(2): 96-104.
[13]
Li ZB, Cai W, Cao Q, et al. 64Cu-labeled tetrameric and octameric RGD peptides for smallanimal PET of tumor alpha(Ⅴ) beta(3) integrin expression[J]. J Nucl Med, 2007, 48(7): 1 162-1 171.
Marinelli L, Lavecchia A, Gottschalk KE, et al. Docking studies on alphaⅤ beta3 integrin ligands: pharmacophore refinement and implications for drug design[J]. J Med Chem, 2003, 46(21): 4 393-4 404.
[16]
Moitessier N, Henry C, Maigret B, et al. Combining pharmacophore search, automated docking, and molecular dynamics simulations as a novel strategy for flexible docking. Proof of concept: docking of arginine-glycine-aspartic acid-like compounds into the alphaⅤ beta3 binding site[J]. J Med Chem, 2004, 47(17): 4 178-4 187.
[17]
Dayam R, Aiello F, Deng J, et al. Discovery of small molecule integrin alphavbeta3 antagonists as novel anticancer agents[J]. J Med Chem, 2006, 49(15): 4 526-4 534.
Feuston BP, Culberson JC, Duggan ME, et al. Binding model for nonpeptide antagonists of alpha(Ⅴ)beta(3) integrin[J]. J Med Chem, 2002, 45(26): 5 640-5 648.
[21]
Raboisson P, Desjarlais RL, Reed R, et al. Identification of novel short chain 4-substituted indoles as potent alphaⅤ beta3 antagonist using structure-based drug design[J]. Eur J Med Chem, 2007, 42(3): 334-343.
[22]
Chen X, Hou Y, Tohme M, et al. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3integrin expression[J]. J Nucl Med, 2004, 45(10): 1 776-1 783.
Zhou Y, Peng H, Ji Q, et al. Discovery of small molecule inhibitors of integrin αⅤβ3 through structurebased virtual screening[J]. Bioorg Med Chem Lett, 2006, 16: 5 878-5 882.
[25]
Chen X, Park R, Tohme M, et al. MicroPET and autoradiographic imaging of breast cancer αⅤ-integrin expression using 18F- and 64Cu-labeled RGD peptide[J]. Bioconjugate Chem, 2004, 15(1): 41-49.
[26]
Janssen ML, Oyen WJ, Dijkgraaf I, et al. Tumor targeting with radiolabeled alpha(Ⅴ)beta(3) integrin binding peptides in a nude mouse model[J]. Cancer Res, 2002, 62(21): 6 146-6 151.
[27]
Janssen M, Oyen WJ, Massuger LF, et al. Comparison of a monomeric and dimeric radiolabeled RGDpeptide for tumor targeting[J]. Cancer Biother Radiopharm, 2002, 17(6): 641-646.
[28]
Beer AJ, Haubner R, Goebel M, et al. Biodistribution and pharmacokinetics of the alphaⅤ beta3-selective tracer 18F-galacto-RGD in cancer patients[J]. J Nucl Med, 2005, 46(8): 1 333-1 341.
[29]
Schnell O, Krebs B, Carlsen J, et al. Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography[J]. Neuro Oncol, 2009, 11(6): 861-870.
[30]
Harris TD, Kalogeropoulos S, Nguyen T, et al. Design, synthesis, and evaluation of radiolabeled integrin alphaⅤ beta3 receptor antagonists for tumor imaging and radiotherapy[J]. Cancer Biother Radiopharm, 2003, 18(4): 627-641.
